Anna Protopapas - 03 Jun 2021 Form 4 Insider Report for Dicerna Pharmaceuticals Inc

Role
Director
Signature
/s/ Douglas W. Pagan, attorney-in-fact
Issuer symbol
N/A
Transactions as of
03 Jun 2021
Net transactions value
$0
Form type
4
Filing time
07 Jun 2021, 21:34:18 UTC
Next filing
19 Jul 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DRNA Common Stock Options Exercise +3,333 3,333 03 Jun 2021 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DRNA Restricted Stock Units Options Exercise $0 -3,333 -100% $0.000000* 0 03 Jun 2021 Common Stock 3,333 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Anna Protopapas is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Common Stock.
F2 Represents RSUs that vested and became nonforfeitable with respect to one-hundred percent (100%) of the total number of RSUs on June 3, 2021.